These findings reveal how the pleiotropic effects of BETi on melanoma cells broadly boost their immunogenicity towards CD8<sup>+</sup> T cells and uncover novel pathways that might be therapeutically exploited to enhance CD8<sup>+</sup> T cell-mediated anti-tumor immunity in <i>ex vivo</i> and <i>in vivo</i> approaches to cancer immunotherapy. The gene discussed is CD8A; the disease is melanoma.